Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Is Back into the Limelight

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is back into limelight after languishing in losses for months amid bruising scandals and internal problems. The stock is up about 14% since the start of this year. Valeant’s CEO Joe Papa is spearheading a great transformation at the company, after which several segments, including Bausch & Lomb/International, Salix, and Dermatology have gotten a throttle. The company has plans to expand its Bausch and Lomb segment in India and China. The segment’s most hot product is Vyzulta, whose sales are estimated to be around $500 million-$1 billion.

Valeant has also cut its liabilities by $1.3 billion. The company is also expected benefit from President Trump’s expected policy to ease drug price restrictions.

Over the current book year the total revenue will be 8,77 billion Dollar (consensus estimates). This is slightly lower than 2016's revenue of 9,67 billion Dollar.

Historical revenues and results Valeant Pharmaceuticals International plus estimates 2017

The analysts anticipate for 2017 a record net profit a 1,29 billion Dollar. The majority of the analysts expects for this year a profit per share of 3,59 Dollar. Based on this the price/earnings-ratio is 4,93.

For this year analysts don't expect the company to pay a dividend.The average dividend yield of the pharmaceutical companies equals a limited 0,49 percent.

Based on the current number of shares Valeant Pharmaceuticals International's market capitalization equals 6,07 billion Dollar.

Tuesday the stock closed at 17,71 Dollar.

Historical stock prices Valeant Pharmaceuticals International past 10 years

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.